围术期补充静脉晶体液预防术后恶心呕吐:Cochrane系统评价简版
本Cochrane系统评价纳入41项随机对照试验,评估全麻手术患者围术期补充静脉晶体液对术后恶心呕吐的预防效果。结果显示,补充晶体液可能降低术后恶心总体风险(RR 0.62,95%CI 0.51-0.75)和呕吐总体风险(RR 0.50,95%CI 0.40-0.63),证据确定性均为中等。
要点
- 围术期补充静脉晶体液可能降低术后恶心总体风险(RR 0.62)。
- 补充晶体液可能降低术后呕吐总体风险(RR 0.50)。
- 益处见于术后6小时内及约24小时。
核心结论
- 围术期补充静脉晶体液可能降低全麻手术患者术后恶心和呕吐的风险,证据确定性为中等。
研究设计与样本
- Cochrane系统评价纳入41项随机对照试验,对象为全麻手术并接受围术期补充静脉晶体液的患者。
主要发现
- 补充晶体液可能降低术后恶心总体风险,RR(95%CI)为0.62(0.51-0.75)(I2=57%,p<0.00001,18项研究;1766例;中等确定性证据)。
- 补充晶体液可能降低术后6小时内恶心风险,RR(95%CI)为0.67(0.58-0.78)(I2=9%,p<0.00001,20项研究;2310例;中等确定性证据)。
- 补充晶体液可能降低术后约24小时恶心风险,RR(95%CI)为0.47(0.32-0.69)(I2=38%,p=0.0001,17项研究;1682例;中等确定性证据)。
- 补充晶体液可能降低术后呕吐总体风险,RR(95%CI)为0.50(0.40-0.63)(I2=31%,p<0.00001,20项研究;1970例;中等确定性证据)。
- 对呕吐的有益效果见于术后6小时内及约24小时。
临床怎么用
- 对全麻手术患者可考虑围术期补充静脉晶体液以降低术后恶心呕吐风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We conducted a Cochrane systematic review on the effectiveness of supplemental intravenous crystalloid administration in preventing postoperative nausea and vomiting. We included randomised controlled trials of patients undergoing surgery under general anaesthesia and given supplemental peri-operative intravenous crystalloid. Our primary outcomes were the risk of postoperative nausea and the risk of postoperative vomiting. We assessed the risk of bias for each included study and applied the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) framework for the certainty of evidence. We included 41 studies. We found that the intervention probably reduces the overall risk of postoperative nausea, the risk ratio (95%CI) being 0.62 (0.51-0.75) (I2 = 57%, p < 0.00001, 18 studies; 1766 participants; moderate-certainty evidence). It also probably reduces the risk of postoperative nausea within 6 h of surgery, with a risk ratio (95%CI) of 0.67 (0.58 to 0.78) (I2 = 9%, p < 0.00001, 20 studies; 2310 participants; moderate-certainty evidence) and by around 24 h, the risk ratio (95%CI) being 0.47 (0.32-0.69) (I2 = 38%, p = 0.0001, 17 studies; 1682 participants; moderate-certainty evidence). Supplemental intravenous crystalloid probably also reduces the overall risk of postoperative vomiting, with a risk ratio (95%CI) of 0.50 (0.40-0.63) (I2 = 31%, p < 0.00001, 20 studies; 1970 participants; moderate-certainty evidence). The beneficial effect on vomiting was seen both within 6 h and by around 24 h postoperatively.
引用
- Jewer JK, Wong MJ, Bird SJ, et al. Supplemental peri-operative intravenous crystalloids for postoperative nausea and vomiting: an abridged Cochrane systematic review. Anaesthesia. 2019. PMID: 31536172. doi:10.1111/anae.14857
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。